Sponsors

Sponsorship packages for the 2025 conference are now available! Please find all further information by clicking the button below:

Sponsorship options 2025

Please find on overview of the sponsors for this years Conference below:

Sponsors List
Compliance / Codex Publication List

Gold Sponsors

Acuitas Therapeutics, Inc. is a Vancouver-based company focused on developing and optimizing lipid nanoparticle (LNP) delivery systems for nucleic acid based therapeutics. We collaborate with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines. Today, we are advancing next-generation LNP to support a variety of modalities. These therapies include targeted LNP for extrahepatic and in vivo CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent infectious disease vaccines, as well as oncology vaccines, including personalized cancer vaccines.

Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron’s expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world’s first mRNA-based personalized CRISPR therapy.

 

With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs). Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

For more information, please visit www.BioNTech.com.

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

 

With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.

We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, NanoAssemblr™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.

FUJIFILM Corporation has been developing proprietary ionizable lipids for LNP formulations. The most advanced one is FL-0445 used in Phase 3 studies of COVID vaccines. We recently developed a safer liver-targeting lipid with a comparable safety profile to one in clinical use by i.v. injection. And we have some candidates for liver de-targeting and also ex-vivo LNPs for KO/KI. 

Hongene is a global CDMO specializing in oligonucleotides and mRNA, with nearly 30 years of RNA-focused expertise. The company offers end-to-end solutions from raw material supply to GMP production of active ingredients and finished drug products. For CRISPR/Cas applications, Hongene uses a chemo-enzymatic approach to deliver sgRNA of any length with high efficiency and precision. Innovation, scalability, and sustainability are integrated into all operations to meet the needs of partners and patients worldwide.

Innorna_300x160_Logo

Innorna is a platform-driven, clinical-stage biotechnology company pioneering RNA medicines through its proprietary lipid nanoparticle (LNP) delivery technologies. With fully integrated capabilities spanning early discovery to commercial-scale manufacturing, Innorna maintains operations across the U.S., Europe, and China.

Innorna’s therapeutic pipeline addresses unmet medical needs across infectious diseases, oncology, chronic and rare disorders, and autoimmune conditions. Several product candidates have advanced into clinical development.

The company has developed a rationally designed, chemically diverse library of over 6,000 ionizable lipids to optimize structure–activity relationships for a broad range of delivery applications. Its innovations are protected by more than 90 global patents—granted or filed—covering LNP and mRNA platform technologies. To learn more, visit www.innorna.com.

We provide solutions to help you overcome your mRNA manufacturing and LNP formulation challenges. Our integrated CTDMO capabilities include the development and manufacturing of custom mRNAs, synthetic lipids, lipid nanoparticle (LNP) formulation and fill and finish. Discover how our capabilities, technical expertise and regulatory know-how can help you deliver and scale up your mRNA-based vaccines and therapeutics, accelerate time to market and mitigate risks.

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines.

Polymun Scientific GmbH
is a private Austrian company, located in Klosterneuburg, offering contract development and manufacturing of biopharmaceuticals as well as development and production of LNP and liposomal formulations. Its patented liposome/LNP technology allows efficient manufacturing of constantly high quality in small and large scale.
Over the last 15 years, Polymun has guided LNP and liposomal formulations into clinical trials, amongst them DNA and different kinds of RNA formulations. A prominent example is Polymun’s contribution to the BioNTech/Pfizer Covid-19 vaccine. Here the team at Polymun Scientific has significantly contributed to the 1st successful mRNA vaccine Comirnaty by optimizing and up-scaling the LNP process as well as by supporting clinical and early market supply.
Polymun is an FDA- and EMA-inspected manufacturer conducting several own R&D projects. For more information, please visit www.polymun.com

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.

vazyme_logo
Company description

Vazyme (688105.SH) is a global biotech supplier dedicated to advancing life science through innovative enzyme technology and continuously expanding the application fields of core technologies in life science, in vitro diagnostics, bio-medicine, and others. By leveraging integrated technology platforms – including single B-cell antibody screening and enzyme-directed evolution.

Vazyme supplies a comprehensive portfolio of R&D reagents and services (including drug discovery reagents, mRNA raw materials, advanced vaccine evaluation tools, and semaglutide synthesis solutions). By upholding rigorous quality standards, producing all molecular materials in-house, and following GMP grade quality control processes, we guarantee a consistent and dependable supply to our global customers.

Company description

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi’s mRNA Center of Excellence (CoE) pursues the development of new mRNA vaccine candidates to address the long-standing challenges in cancer, immune-mediated diseases, and rare diseases, focusing on thermostability and tolerability.

Company description

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi’s mRNA Center of Excellence (CoE) pursues the development of new mRNA vaccine candidates to address the long-standing challenges in cancer, immune-mediated diseases, and rare diseases, focusing on thermostability and tolerability.

Silver Sponsors

ARCALIS, Inc. is a CDMO that manufactures mRNA therapeutic drugs for vaccines targeting cancer and rare diseases, along with infectious diseases, providing our customers with seamless services from mRNA design to large-scale manufacturing.

Our commercial production of self-amplifying mRNA (saRNA)-LNP, KOSTAIVE, for the COVID-19 vaccine, started in 2024 at our drug substance facility.

“Genevant Sciences is a leading nucleic acid delivery solutions company with best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology. Our selective collaboration business model enables us to partner with innovative payload companies in the gene editing, and RNA editing, therapeutic and vaccine spaces to bring emerging technologies into and through the clinic.

 

Our leadership position, built over more than two decades focused on nucleic acid development and delivery, is reflected in the first approved RNA-LNP product (Onpattro® marketed by Alnylam) and the industry’s most robust and expansive LNP patent portfolio. Currently our research focus is to expand the therapeutic reach of LNPs to T cells, hematopoietic stem cells and other traditionally hard to reach tissues/cell types.

 

We are here to help you bring your nucleic acid-based medicines to patients!”

Primrose Bio develops new manufacturing solutions for next generation therapeutics and vaccines. Primrose’s major offerings include Pfenex Expression Technology®, a Pseudomonas fluorescens-based protein expression platform; Prima RNApols™, superior RNA polymerases for mRNA manufacturing; and PeliCRM197®, a commercially validated carrier protein for conjugate vaccines. Leading pharmaceutical companies, including Merck, Jazz Pharmaceuticals, and Serum Institute of India, use Primrose’s technologies. Visit: www.primrosebio.com.

Recipharm Advanced Bio | CDMO Delivering on the Promise of Advanced Therapies

 

Recipharm Advanced Bio, the advanced therapies division of Recipharm, is a CDMO focused on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). Our specialized capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

 

With state-of-the-art facilities in Boston, Portugal and Germany, Recipharm Advanced Bio collaborates with innovators to support increased product quality, speed to market, and reduced costs—ultimately improving access for patients worldwide.

 

Recipharm Advanced Bio, ADVANCING TOGETHER

Roche CustomBiotech is a key partner for leading mRNA innovators, supplying the critical raw material solutions needed to bring their groundbreaking therapeutics to life. Our broad portfolio of high quality GMP Grade nucleotides, RNA and DNA polymerases, capping enzymes as well as DNA nucleases and proteases for mRNA cleanup, continually evolves through close collaboration with mRNA innovators, ensuring we meet the dynamic demands of the mRNA landscape. 

By staying ahead of market developments, Roche CustomBiotech empowers the creation of a new generation of mRNA therapeutics. Our core principle is to minimize variation of products built on our raw materials by ensuring high quality, high performance within narrow tolerances, and providing reliable supply.

Wacker Biotech is the CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. Having recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany, we can produce at diverse scales supplies of early R&D to GMP material for gene and cell therapies and vaccines (delivered via both viral and non-vector modalities), with full QC release according to US Pharmacopeia and EU draft guidelines. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization.

 

Complementing our bioprocess development and manufacturing experts at our five global sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. This includes providing strategies for mRNA capping, co-transcriptionally and post-transcriptionally. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry advances. We have 30+ years of experience developing biologics to advance human and animal health.

Sanofi_logo

About Sanofi  

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. 

Sanofi’s mRNA Center of Excellence (CoE) pursues the development of new mRNA vaccine candidates to address the long-standing challenges in cancer, immune-mediated diseases, and rare diseases, focusing on thermostability and tolerability.

Roche CustomBiotech is a key partner for leading mRNA innovators, supplying the critical raw material solutions needed to bring their groundbreaking therapeutics to life. Our broad portfolio of high quality GMP Grade nucleotides, RNA and DNA polymerases, capping enzymes as well as DNA nucleases and proteases for mRNA cleanup, continually evolves through close collaboration with mRNA innovators, ensuring we meet the dynamic demands of the mRNA landscape. 

By staying ahead of market developments, Roche CustomBiotech empowers the creation of a new generation of mRNA therapeutics. Our core principle is to minimize variation of products built on our raw materials by ensuring high quality, high performance within narrow tolerances, and providing reliable supply.

Wacker Biotech is the CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. Having recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany, we can produce at diverse scales supplies of early R&D to GMP material for gene and cell therapies and vaccines (delivered via both viral and non-vector modalities), with full QC release according to US Pharmacopeia and EU draft guidelines. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization.

 

Complementing our bioprocess development and manufacturing experts at our five global sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. This includes providing strategies for mRNA capping, co-transcriptionally and post-transcriptionally. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry advances. We have 30+ years of experience developing biologics to advance human and animal health.

Bronze Sponsors

Anemocyte is an Italian Biotech Manufacturing Organization with a strong focus on the research,  development, manufacturing, and analytical services and products to address needs in the field of:

· pDNA – Plasmids (R&D, Hiqh-Quality, and GMP) for Viral Vector and mRNA;

· mRNA – mRNA (R&D) for vaccines and therapeutic treatments.

Our experience:

25 years of research, development and manufacturing experience (from R&D to GMP) in the field of Cell and Gene Therapies and Nucleic Acids.

Biomay is a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, Biomay has specialized in the expression of recombinant proteins in E. coli from its inception. Today, the company provides cGMP services for the manufacturing of messenger RNA (mRNA), circular plasmid DNA, linear IVT-template DNA, and therapeutic recombinant proteins.

Biomay operates a dedicated mRNA Competence Center for cGMP manufacturing and QC testing of mRNA drug substance and drug product (clinical and commercial). Services include process and analytical development, cell banking, R&D material supply, cGMP manufacturing, lipid nanoparticle (LNP) formulation, and aseptic filling. Biomay’s facilities are inspected by the US FDA.

BIOVECTRA, now a part of Agilent, is a leading North American contract development and manufacturing organization (CDMO) specializing in the production of complex biologics, nucleic acids, and synthetic molecules. With state-of-the-art facilities and over 50 years of expertise, BIOVECTRA delivers integrated solutions that support clients from early development through commercial supply. Our nucleic acid manufacturing capabilities span plasmid DNA (pDNA), messenger RNA (mRNA), lipid nanoparticle (LNP) formulation, and end-to-end fill/finish services. From microbial fermentation to final sterile drug product, we provide seamless, scalable solutions that reduce risk, shorten timelines, and ensure the highest quality standards. Beyond nucleic acids, BIOVECTRA offers proven experience in microbial-based biologics, highly potent APIs, complex chemistry, and GMP-grade bioreagents. By combining versatility with deep scientific expertise, BIOVECTRA helps biopharmaceutical partners bring life-changing therapies to patients worldwide.

Croda Pharma stands at the forefront of pharmaceutical innovation, specialising in the development of high purity materials for advanced drug formulations. Our expertise spans high purity excipients, innovative lipids, vaccine adjuvant excellence, plus protein delivery and bioprocessing ingredients. By leveraging our extensive knowledge and cutting-edge technologies, we enable next-generation drug delivery solutions that cater to both human and animal health markets. Our pharmaceutical portfolio is unmatched in its quality and effectiveness, ensuring that we meet the most stringent industry standards.

 

As part of Croda, Avanti Research is the bridge to researchers worldwide. Croda Pharma is the scale-up engine. Together, we support your discoveries – from research innovation to GMP excellence – and we’re proud to empower that journey. Capitalise on our diverse portfolio and breadth of knowledge to bring the next generation of safe and effective therapeutics into the world.

 

We have substantial investment in GMP and multi-site EXCiPACT accreditation, demonstrating every day the confidence in both ingredient quality and supply chain security.

Certest Pharma is dedicated to the development of new solutions for nucleic acid therapeutics through innovative delivery solutions. Specializing lipid nanoparticles (LNP) technology, Certest has developed a proprietary library of ionizable lipids, resulting from a thorough screening over 1,000 lipids. Thus, Certest offers tailor-made, high-performance ionizable lipids with exceptional thermostable LNP properties. Additionally, its RNA platform supports the design, synthesis, scale-up, and evaluation of RNA and oligonucleotides, featuring proprietary UTR sequences, codon optimization software, and in-house production of mRNA synthesis enzymes for superior expression.

Logo from Curapath

Curapath, is a global CDMO specialized in the tailored design, development, and GMP manufacturing of cutting-edge polymer and lipid-based drug delivery systems. Our customers benefit from our unique expertise, operational excellence and technical solutions in polymer nanoparticles (PNPs) and lipid nanoparticles (LNPs) along with their essential components.

In addition, we have a broad catalogue of innovative PEG-Free polymers and lipids that are easily assembled in safe, biodegradable and non-immunogenic nano-carriers

At Curapath, we stand as your partner from discovery stages to commercial GMP scale-up.

With our dedicated support, expertise, and state of the art manufacturing capabilities, we assure you a guaranteed path for your drug to navigate through clinical development and reach commercialization seamlessly

Your success is our commitment

Evonik’s Health Care business line is a fully integrated solutions provider for advanced drug delivery and can support you at any stage of the drug development process, including manufacturing of pharmaceutical excipients, developing innovative formulations, as well as the production of clinical drug product through commercial quantities.

As one of the world’s leading specialty chemicals, Evonik focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023.

Logo from GenScript

GenScript Biotech is a world leading technology and service provider of life science R&D and manufacturing, founded in 2002 as one of the first commercialize gene synthesis providers. GenScript provides life sciences services and products to scientists in over 200 countries worldwide, including mRNA & circular RNA synthesis, gene and gene fragments synthesis, DNA/RNA/NGS/qPRC/tRNA, & siRNA oligos, custom peptide synthesis, complex protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology, as well as a variety of other research-focused catalogue products. After two decades of rapid growth, the company has expanded its business in recent years into the fields of immunotherapy and early-phase drug discovery services, CDMO and microbiology. Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript strives to become the most trustworthy biotech company in the world. GenScript offers global support for its loyal customers with dedicated sites in the Netherlands and the UK and a strong global remote workforce.

Hanmi Fine Chemical has developed a novel 5’ cap analog series which could be applied to co-transcriptional mRNA and saRNA synthesis. The current HanmiCap® series consists of two AG cap analogs (HC07, HC13) and two AU cap analogs (HC11, HC20). While HC07 showed comparable results against the commercial cap, HC13 and HC11 demonstrated significantly higher translation levels in vivo. HC13 in particular, is demonstrating significantly reduced dsRNA (double-stranded RNA) levels which is an essential factor for therapeutic development in the mRNA field. Hanmi Fine Chemical is delighted to present HanmiCap®, ensuring exceptional outcomes in the development of your mRNA therapeutics.

Hzymes Biotechnology has developed hundreds of raw materials related to biopharmaceutical and vaccine production based on the technology platforms of enzyme gene mining and performance characterization, enzyme molecule optimization and modification, high throughput screening of enzyme genes, organic synthesis, synthetic biology, and R&D and preparation of antigens and antibodies, etc. Hzymes Biotechnology can provide customers with a full set of enzyme raw materials required for the production of mRNA drugs and vaccines, as well as various types of T7 RNA polymerase mutants, chemical substrates, cap analogs, etc.We also have a pharmaceutical-grade special enzyme production system with a super-large production scale and super-high equipment standards. It has provided products and services to more than 300 domestic manufacturers of bio-pharmaceuticals, vaccine preparations, and in vitro diagnostic reagents. Meanwhile, our products have been exported to 25 overseas countries and regions.

At InsideTx, we’re redefining nanoparticle manufacturing to unlock the full potential of RNA-LNP therapeutics and nanomedicines.

By merging microfluidics and biotechnology, we provide truly end-to-end nanoparticle formulation solution—streamlining your journey from early screening to large-scale GMP production.

First, meet TAMARA—our all-in-one R&D platform designed for minimal sample loss, reusable microfluidic chips, and unmatched flexibility across every stage of development, from initial formulation screening to in-vivo studies.  It’s the ultimate solution for RNA-LNP and nanomedicine research—and our users say it best: “I’m absolutely blown away by how user-friendly, efficient, and straightforward this system is!”

And we’re just getting started. Our patented next-generation manufacturing technology seamlessly scales – from microliter volumes to continuous, tens-of-liters GMP production— ensuring that you deliver identical nanoparticle quality and characteristics at every scale.

From liposomes and RNA-LNPs to SLNs, PLGAs, and beyond—InsideTx empowers your innovations, accelerates your development timelines, and maximizes your chances of success.

KNAUER manufactures high-quality scientific instruments for research, routine analysis, and quality assurance. The supported technologies include liquid chromatography, precise pumping and dosing of liquids at high pressures, as well as the detection of dissolved substances in liquid streams. Configurable products and customized solutions are among our key strengths. All products are developed and manufactured in Berlin.

Developing instruments that help people in laboratories gain new insights and make their work easier — that is the spirit in which KNAUER was founded and which continues to drive the company today.

As experts in liquid chromatography, we carry forward what our founder, Dr. Herbert Knauer, began: together with laboratory users, we develop innovative and customized solutions. We are curious and creative — making us the ideal partner for anyone seeking more than standard solutions.

KNAUER is a global partner of science. We support research and progress — now and in the future.

Lonza_Logo

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of around 18,500 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. 

While Lonza provides services across numerous therapeutics technologies, for the purposes of this event Lonza offers development and cGMP manufacturing services for RNA drug substances and LNP formulations. Lonza has an established RNA platform to enable quick translation into clinical manufacturing and has access to various mixing technologies to enable a wide breadth of LNP formulations. 

For 50 years, New England Biolabs (NEB) has pioneered the discovery and production of innovative products tailored for molecular biology research. Our commitment to scientific discovery is evident in all that we do, including our ever-expanding product portfolio, investment in our basic and applied research program, and support of customers’ research in academia and industry, including cutting-edge technologies for use in molecular diagnostics and nucleic-acid vaccines development. Guided by our founding principles, NEB proactively invests in efforts to improve the well-being of our employees, surrounding communities, as well as the future of our planet. NEB remains a privately held company with global reach, supported by our headquarters in Ipswich, MA, USA, subsidiary offices in 10 countries, and over 60 distribution partners around the world. For more information about New England Biolabs, visit www.neb.com.

NEB® and NEW ENGLAND BIOLABS® are registered trademarks of New England Biolabs, Inc.

Discover Promega, your trusted scientific partner for over 40 years. In the rapidly advancing field of mRNA therapeutics, Promega supports the entire workflow: from template DNA and in vitro transcription (IVT) to RNA purification, quality control, and cGMP-grade raw materials for scalable, regulatory-compliant production. Our analytical toolbox includes dsRNA detection assays, RNA quantitation, sequence identity confirmation, and functional reporter assays to ensure integrity, safety, and efficacy of mRNA products. Through our technical expertise and dedicated services, we support partners in driving innovation and achieving reliable results.

Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization. 

For more information about Quantoom Biosciences, visit www.quantoom.com

We are a Dutch mRNA technology provider and mRNA manufacturer (R&D- and GMP-grade) supporting over 250 customers worldwide in the design, synthesis, of high-quality mRNA and LNP formulation for various applications including vaccination and therapeutic use. We offer a range of services that enable mRNA therapy pioneers to develop the medicines of the future: from mRNA design, to R&D- and GMP-grade manufacturing of (LNP-formulated) mRNA, and contract research services; our one-stop-shop has you covered.

In addition, our licensable technologies on mRNA design, manufacturing processes and LNP formulations provide our customers a head start in the competitive marketplace.

Finally, RIBOPRO is developing a proprietary flow-based, fully automated production and GMP compliant system, delivering an event greater scaling flexibility, combined with ultra-fast production timelines.

Sartorius is a leading global partner of the biopharmaceutical industry dedicated to enabling cell and gene therapy developers to manufacture and commercialize their advanced therapy medicinal products (ATMPs). Over the last decade the company has expanded its legacy portfolio of single-use bioprocessing solutions through the acquisition of complementary advanced therapy consumables, services, and technologies—from plasmid engineering and manufacturing to cell culture media, reagents and monolithic chromatography. Sartorius’ advanced therapy solutions are designed to overcome current ATMP production challenges by enhancing productivity, improving process economics, and supporting safe and regulatory compliant manufacturing. Sartorius products are currently used in approved cell and gene therapies and actively support clinical pipelines worldwide. The company’s continued investment in innovative solutions demonstrates their commitment to advancing the field and making access to these life-saving treatments a reality.  

Waterfall_logo

With scores of biotech/pharma companies now exploring their applications across myriad therapeutic indications, mRNA medicines are the future.  But current mRNA manufacturing processes are stuck in the past, plagued by deleterious side products requiring onerous purification procedures. Waterfall Scientific aims to change that.  Our patented DuoTetherTM technologies offer a paradigm shift:  co-tethering both the DNA template and RNA polymerase to a surface (either a magnetic bead or inside a fluidic chamber) virtually eliminates deleterious side product production, offering superior mRNA quality while minimizing purification requirements.  We are a team of world-renowned mRNA and fluidics experts with proven track records, dedicated to developing the technology to provide researchers with the high-quality, custom mRNA they need to accelerate groundbreaking therapies.

Waterfall_logo

With scores of biotech/pharma companies now exploring their applications across myriad therapeutic indications, mRNA medicines are the future.  But current mRNA manufacturing processes are stuck in the past, plagued by deleterious side products requiring onerous purification procedures. Waterfall Scientific aims to change that.  Our patented DuoTetherTM technologies offer a paradigm shift:  co-tethering both the DNA template and RNA polymerase to a surface (either a magnetic bead or inside a fluidic chamber) virtually eliminates deleterious side product production, offering superior mRNA quality while minimizing purification requirements.  We are a team of world-renowned mRNA and fluidics experts with proven track records, dedicated to developing the technology to provide researchers with the high-quality, custom mRNA they need to accelerate groundbreaking therapies.

Waterfall_logo

With scores of biotech/pharma companies now exploring their applications across myriad therapeutic indications, mRNA medicines are the future.  But current mRNA manufacturing processes are stuck in the past, plagued by deleterious side products requiring onerous purification procedures. Waterfall Scientific aims to change that.  Our patented DuoTetherTM technologies offer a paradigm shift:  co-tethering both the DNA template and RNA polymerase to a surface (either a magnetic bead or inside a fluidic chamber) virtually eliminates deleterious side product production, offering superior mRNA quality while minimizing purification requirements.  We are a team of world-renowned mRNA and fluidics experts with proven track records, dedicated to developing the technology to provide researchers with the high-quality, custom mRNA they need to accelerate groundbreaking therapies.

Basic Sponsors

As one of the largest independent contract laboratories in Europe, Labor LS provides analytical services to more than 1,000 clients according to cGMP standards in the fields of microbiology, biochemistry, molecular biology, and chemical-physical analysis. 
With the goal of offering comprehensive, one-stop services to support the development and release of the most advanced pharmaceutical products, Labor LS carries out method validations, verifications, and routine testing with over 600 experts and approximately 7,000 m² of laboratory space, working in close cooperation with its customers.

Immagina Bio advances RNA and ribosome biology by enabling scientists to study translation in action. Our integrated suite of technologies—including high-throughput ribosome profiling, ribosome isolation, native-tRNA sequencing, cell-free RNA fragmentomics, and RNA modification detection—delivers unprecedented insights into protein synthesis. We empower academic researchers and pharmaceutical companies to develop more efficient, effective, and safer therapeutics, along with more informative biomarkers

preclinics GmbH is a Potsdam (GER) -based leading Contract Research Organization (CRO). We are specialized in the early preclinical development of biologics, vaccines, and therapeutic candidates. Our integrated preclinical services accelerate the translation of mRNA-based therapies and vaccines from bench to clinic. 

With more than 15 years of scientific excellence, preclinics combines cutting-edge technologies, comprehensive in vitro and in vivo models, and a collaborative mindset to deliver high-quality, reliable data for decision-making in drug development. 

Our preclinical portfolio covers: 

  • Translational in vivo PK/PD models for mRNA delivery systems 
  • Reporter gene analysis via in vivo imaging, ddPCR and protein quantification 
  • Biomarker-driven efficacy studies. 
  • Immunogenicity and antibody response profiling for mRNA candidates. 
  • Formulation testing and comparative studies for LNP and non-LNP technologies.

     

We invite you to visit our representative to discuss how preclinics can advance your mRNA program — from concept to preclinical validation. 

Driven by innovation and a strong commitment to scientific integrity, animal welfare, and the 3R principles, and as a signatory of the Marseille Declaration, preclinics is your trusted partner for translational preclinical solutions that move ideas efficiently and responsibly toward clinical success. 

In collaboration with Taconic Biosciences, preclinics provides access to 4.600 transgene models and custom GEM services, empowering our partners to explore disease mechanisms and validate therapeutic targets with exceptional translational relevance. 

For more information please visit www.preclinics.com

 

 

Exothera is a contract, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of vaccines, viral vectors, oncolytic viruses, and nucleic acids. For more information, visit www.exothera.world.

Kudo Biotechnology, Inc (Kudo Bio) is a leading global contract development and manufacturing organization (CDMO), providing world-class, end-to-end mRNA manufacturing solutions all under one roof, as well as commercial fill-finish. Kudo Bio is headquartered in the US and has state-of-the-art facilities including a Process Science Center of Excellence in Needham, Massachusetts, a clinical GMP manufacturing facility and MSAT laboratories in Shanghai, with additional presence in Singapore. Our GMP manufacturing facility spans over 57,000 sqf, designed in accordance with cGMP and global regulatory guidelines, and our production lines cater for preclinical through Phase 3 and commercial. We also offer Fill & Finish, Testing & Release, and Supply Chain Management, and for mRNA and LNP manufacturing we also offer Process and Analytical Development and Technology Transfer. Kudo Bio has a robust quality management system to ensure the highest quality and to comply with global regulations. For more information, please visit www.kudobio.com.

NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF’s lipid nanoparticle platform for nucleic acid delivery composed of COASOMEⓇ SS Series, a novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF LNP platform is becoming adopted in clinical planning by NOF collaborators.

uBriGene Biosciences is your bridge from ATMPs concept to commercialization. Our CDMO+ services include cell therapy products (CAR-T, TCR-T, NK Cells, iPSC, Dendritic cells, Macrophages), viral vectors (AAV, LVV, RVV, AdV, oncolytic viruses), plasmids, and RNA (mRNA, circRNA, acRNA).

Our extensive experience in manufacturing, QC testing, and regulatory filing support of ATMPs, from early discovery to commercialization, will accelerate your therapeutic programs from bench to bedside.

With four Centers of Excellence in North America, and Asia Pacific and more than 20 GMP clean room suites, uBriGene supports global CGT, vaccine, and RNA product development.

Company description

Kudo Biotechnology, Inc (Kudo Bio) is a leading global contract development and manufacturing organization (CDMO), providing world-class, end-to-end mRNA manufacturing solutions all under one roof, as well as commercial fill-finish. Kudo Bio is headquartered in the US and has state-of-the-art facilities including a Process Science Center of Excellence in Needham, Massachusetts, a clinical GMP manufacturing facility and MSAT laboratories in Shanghai, with additional presence in Singapore. Our GMP manufacturing facility spans over 57,000 sqf, designed in accordance with cGMP and global regulatory guidelines, and our production lines cater for preclinical through Phase 3 and commercial. We also offer Fill & Finish, Testing & Release, and Supply Chain Management, and for mRNA and LNP manufacturing we also offer Process and Analytical Development and Technology Transfer. Kudo Bio has a robust quality management system to ensure the highest quality and to comply with global regulations. For more information, please visit www.kudobio.com.

Company description

uBriGene Biosciences is your bridge from ATMPs concept to commercialization. Our CDMO+ services include cell therapy products (CAR-T, TCR-T, NK Cells, iPSC, Dendritic cells, Macrophages), viral vectors (AAV, LVV, RVV, AdV, oncolytic viruses), plasmids, and RNA (mRNA, circRNA, acRNA).

Our extensive experience in manufacturing, QC testing, and regulatory filing support of ATMPs, from early discovery to commercialization, will accelerate your therapeutic programs from bench to bedside.

With four Centers of Excellence in North America, and Asia Pacific and more than 20 GMP clean room suites, uBriGene supports global CGT, vaccine, and RNA product development.

Found in 1998, Hongene is an end-to-end partner for specialist nucleic acid manufacturing, offering a wide range of products to meet the needs of the life sciences industry. From standard raw material building blocks to complex oligonucleotides and mRNA, Hongene consistently delivers with exceptional quality and value. Our world-leading manufacturing capacity of phosphoramidites is 58 tons and 54,000 liters for NTP per year, sufficient to support customers from small-scale to commercial production.